| Finding | Percentage | Cases |
|---|---|---|
| Gender | ||
| Male | 66.7% | 16/24 |
| Female | 33.3% | 8/24 |
| Indifferent | 0% | 0/24 |
| Unknown | 0% | 0/24 |
| General | ||
| 4.2% | 1/24 | |
| 4.2% | 1/24 | |
| 4.2% | 1/24 | |
| 16.7% | 4/24 | |
| 20.8% | 5/24 | |
| 37.5% | 9/24 | |
| 95.8% | 23/24 | |
| 95.8% | 23/24 | |
| 91.7% | 22/24 | |
| 86.4% | 19/22 | |
| Neurology | ||
| 95.8% | 23/24 | |
| 75% | 18/24 | |
| 54.2% | 13/24 | |
| Facial abnormalities | ||
| 50% | 12/24 | |
| 62.5% | 15/24 | |
| 29.2% | 7/24 | |
| 58.3% | 14/24 | |
| Visual and hearing impairments | ||
| 4.2% | 1/24 | |
| 58.3% | 14/24 | |
| Heart | ||
| 16.7% | 4/24 | |
| Pulmonary | ||
| 25% | 6/24 | |
| Gastrointestinal | ||
| 75% | 18/24 | |
| Urogenital | ||
| 25% | 6/24 | |
| Skeleton | ||
| 66.7% | 16/24 | |
| Skin / Hair / Nails | ||
| 25% | 6/24 | |
| Endocrine / Immunological / Metabolic | ||
| 4.2% | 1/24 | |
| 8.3% | 2/24 | |
| 16.7% | 4/24 | |
| Neoplasia | ||
| Neoplasia | 0% | 0/24 |
| Inheritance | ||
| 100% | 24/24 | |
CYFIP2